Gram Negative Bacterium (e.g., Escherichia Coli, Salmonella, Helicobacter, Etc.) Patents (Class 514/2.8)
  • Patent number: 11452758
    Abstract: A novel antimicrobial peptide derived from LL37 peptide has not only an excellent antimicrobial activity for Gram-positive bacteria, Gram-negative bacteria, and antibiotic tolerant bacteria but also low cytotoxicity for cells derived from mouse or human. It can be advantageously used as an effective component of antimicrobial antibiotics, cosmetic composition, food additive, animal feed additive, biopesticides, and quasi-drug.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 27, 2022
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
    Inventors: Yoonkyung Park, Eunji Park
  • Patent number: 11279733
    Abstract: There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 22, 2022
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Matthew Cooper, Mark Blaskovich, Alejandra Gallardo-Godoy, Karl Hansford, Alysha Elliott, Craig Muldoon, Bernd Becker
  • Patent number: 11235027
    Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: February 1, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter Luke Santa Maria, Yunzhi Peter Yang, Sungwoo Kim, Chloe Domville-Lewis
  • Patent number: 11066443
    Abstract: The present invention relates to compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof for the use in the treatment or prevention of infections and resulting diseases caused by Pseudomonas aeruginosa.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Kurt Amrein, Konrad Bleicher, Bernhard Fasching, Hans Hilpert, Sabine Kolczewski, Carsten Kroll, Adrian Schaeublin, Claudia Zampaloni
  • Patent number: 10576126
    Abstract: [Problem] To provide a highly safe and efficacious antitumor agent that is derived from probiotics. [Solution] The present invention relates to an antitumor agent comprising a compound represented by formula (1) or a complex thereof as an active ingredient. In formula (1): R1 represents a hydrogen atom or a hydroxymethyl group; R2 represents a hydrogen atom, a methyl group or a hydroxymethyl group; and R3, R4 and R5 each independently represent a methyl group, an N5-(trans-5-hydroxy-3-methylpent-2-enoyl) group, an N5-(cis-5-hydroxy-3-methylpent-2-enoyl) group or an N5-(trans-4-carboxy-3-methylpent-2-enoyl) group. According to the present invention, a highly safe and efficacious antitumor agent can be provided.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: March 3, 2020
    Assignee: National University Corporation Asahikawa Medical University
    Inventors: Mikihiro Fujiya, Hiroaki Konishi, Kentaro Moriichi
  • Patent number: 9867870
    Abstract: The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 16, 2018
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 9642896
    Abstract: The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: May 9, 2017
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 9598471
    Abstract: A bacteriocin produced constitutively by Streptococcus thermophilus strain 110 (NRRL B59671), thermophilin 110, kills and/or inhibits the growth Streptococcus pyogenes, Streptococcus mutans, and/or Propionibacterium acnes. Thermophilin 110 is the first bacteriocin identified with this activity. Thus, compositions containing thermophilin 110 and/or Streptococcus thermophilus strain 110 (NRRL B59671) can be used to prevent and/or treat diseases caused by Streptococcus pyogenes, Streptococcus mutans, and/or Propionibacterium acnes. Such diseases include strep throat, dental caries, and acne, respectively. Methods to inhibit the growth of these bacteria and/or treat the diseases are also included.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: March 21, 2017
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: John A Renye, Jr., George A Somkuti
  • Patent number: 9562255
    Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: February 7, 2017
    Assignee: The MITRE Corporation
    Inventor: Michael Heath Farris
  • Patent number: 9556228
    Abstract: This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to compositions and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as Staphylococcus aureus. According to the invention, the object is attained in a first aspect by a peptide according to claim 1.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: January 31, 2017
    Assignee: UNIVERSITAET LEIPZIG
    Inventors: Ralf Hoffmann, Daniel Knappe, Kai Hilpert, Ralf Mikut, Serge Ruden
  • Patent number: 9556224
    Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: January 31, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin Neville Shelton
  • Patent number: 9358284
    Abstract: The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 7, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Allan James Saul, Francesca Micoli
  • Patent number: 9139626
    Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: September 22, 2015
    Assignee: THE MITRE CORPORATION
    Inventor: Michael Heath Farris
  • Publication number: 20150148286
    Abstract: Provided are compositions and methods for potentiating the effect of antibiotics. The compositions comprise a non-covalent complex of alpha-lactalbumin and fatty acid. The fatty acids are cis, unsaturated, C14 to C20 fatty acids. The complex and antibiotic can be administered to an individual together or separately. The antibiotic may be one to which resistance has developed.
    Type: Application
    Filed: July 5, 2013
    Publication date: May 28, 2015
    Inventors: Anders P. Hakansson, Laura R. Marks, Hazeline Hakansson
  • Publication number: 20150141324
    Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 21, 2015
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Publication number: 20150126435
    Abstract: Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the E. coli sequence type 131 (ST131). Also disclosed are methods and assay kits useful in detecting the presence of the distinct subtype of E. coli and methods of treating a subject suffering from an infection from a subclone of ST131.
    Type: Application
    Filed: July 2, 2013
    Publication date: May 7, 2015
    Inventors: Lance B. Price, Evgueni V. Sokurenko, James R. Johnson
  • Patent number: 9018158
    Abstract: The invention provides a method of overcoming resistance to at least one antibiotic in a multidrug resistant bacterium, said method comprising contacting said bacterium with an alginate oligomer together with the antibiotic. The multidrug resistant bacterium may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antibiotic in treating a subject infected, suspected to be infected, or at risk of infection, with a multidrug resistant bacterium to overcome resistance to the antibiotic in said multidrug resistant bacterium. In another aspect the method can be used to combat contamination of a site with multidrug resistant bacteria, e.g. for disinfection and cleaning purposes.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: April 28, 2015
    Assignee: Algipharma AS
    Inventors: Edvar Onsoyen, Rolf Myrvold, Arne Dessen, David Thomas, Timothy Rutland Walsh
  • Publication number: 20150104492
    Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Alison McDermott, Marialuisa Mangoni
  • Patent number: 8999924
    Abstract: The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: April 7, 2015
    Assignee: N.V. Nutricia
    Inventors: Gilda Elise Georgi, Marco Euler, Marko Mank, Andreas Hensel, Michael Niehues, Monika Klapperich, Bernd Stahl
  • Patent number: 8999922
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: April 7, 2015
    Assignee: RQX Pharmaceuticals, Inc.
    Inventors: Robert I. Higuchi, Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Prasuna Paraselli
  • Publication number: 20150093370
    Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN
  • Patent number: 8987193
    Abstract: The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: March 24, 2015
    Assignee: University College Cork—National University of Ireland, Cork
    Inventors: Paul Cotter, Colin Hill, Desmond Field
  • Publication number: 20150080289
    Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 19, 2015
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Publication number: 20150080291
    Abstract: Disclosed are peptides having biological and therapeutic activity. Particularly disclosed are lipidated di- or tri-peptides analogs of KPV or KdPT that exhibit antimicrobial activity. In particular, the peptides of this invention provide enhanced anti-microbial activity over the base tri-peptides, lysine-proline-valine and lysine-d-proline-tyrosine. The disclosed peptides have the general formula of C12-18 lipid-KXZ-NH2i wherein K is lysine; X is proline, d-proline, histidine or arginine; Z is optional and if present Z is valine, threonine, alanine or leucine; and the terminal COOH is NH2 amidated. The C12-18 lipid is preferably the lipid moiety of lauric acid (C12), myristic acid (C14), pentadecanoic acid (C15), palmitic acid (C16), or stearic acid (C18). The invention is further related to methods of using of these peptides to treat various insults, inflammations or bacterial infections affecting the skin and other related mucosal body surfaces such as the oral cavity.
    Type: Application
    Filed: March 7, 2013
    Publication date: March 19, 2015
    Inventors: Lijuan Zhang, Robin Carmichael
  • Patent number: 8980279
    Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 17, 2015
    Assignee: Qu Biologics
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Publication number: 20150072920
    Abstract: The present invention relates to an antimicrobial composition having activity against Gram-positive and Gram-negative bacteria. The composition is a) a composition comprising at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; b) a composition comprising at least two bacteriocin selected from the group consisting of pediocin, Nisin and reuterin; c) a composition comprising pediocin and at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; or d) a composition comprising reuterin and at least one organic acid selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid. The present invention also relates to the use of said compositions for sanitizing and/or disinfecting surfaces and method thereof.
    Type: Application
    Filed: April 15, 2013
    Publication date: March 12, 2015
    Applicant: CASCADES CANADA ULC
    Inventors: Ismail Fliss, Pierre Hudon, Marie-Helene Charest, Nathalie Comeau
  • Publication number: 20150072922
    Abstract: Described herein are compounds and compositions comprising antimicrobial peptides and methods for their use.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Inventors: David Hains, Andrew Schwaderer, Huanyu Wang
  • Publication number: 20150065416
    Abstract: There is provided inter alia a method of treating microbial infection comprising administering to a subject in need thereof a therapeutically effective amount of: (a) 4-(4-ethyl-5-fluoro-2-hydroxyphenoxy)-3-fluorobenzamide; and (b) an antibacterial agent selected from the group consisting of carbapenems, aminoglycosides, polymixins, glycylcyclines, rifampifin and sulbactam.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Coralie Mouzé, Vincent Gerusz, Alexis Denis
  • Patent number: 8962801
    Abstract: Neisseria meningitidis PorA constructs are provided which have one or more disrupted variable regions created by insertion of entire conserved regions or conserved region amino acids. The highly immunogenic variable regions of PorA are responsible for eliciting strain-specific immune responses that are not broadly protective, so disruption of the variable regions directs the immune response against conserved region epitopes to effectively immunize against a broader spectrum of N. meningitidis strains. Also provided are encoding nucleic acids, genetic constructs, host cells expressing the PorA constructs and compositions, kits and methods for detection and treatment of Neisseria meningitidis infections.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: February 24, 2015
    Assignee: Griffith University
    Inventors: Michael Paul Jennings, Ian Richard Anselm Peak
  • Publication number: 20150045288
    Abstract: The present invention relates to anti-contaminant composition comprising a cell-free fermentation product of one or more Bacillus subtilis strains (e.g., selected from the group consisting of: 22C-P1, 15A-P4, 3A-P4, LSSA01, ABP278, BS 2084 and BS 18); wherein said fermentation product comprises one or more compounds selected from the group consisting of: a lipopeptide, a polyketide, a bacillibactin, a bacilysin, an anticapsin, a plantazolicin, a LCI, a homologue of a plantazolicin and a homologue of a LCI. In addition, the present invention further relates to methods of preparing the compositions, methods of using the composition, products comprising the composition and uses thereof.
    Type: Application
    Filed: February 20, 2013
    Publication date: February 12, 2015
    Inventors: Tina Mygind, George H. Weber, Connie Benfeldt, Ashley Ann Hibberd, Rebecca Joy Landrum, Panagiotis Chanos, Gregory R. Siragusa, Matthew James Hundt
  • Publication number: 20150045287
    Abstract: The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from Lilium ‘Stargazer’ glycine-rich protein 1. In addition, the present invention provides an antimicrobial composition comprising an antimicrobial peptide of the invention, an additional biocidal agent and pharmaceutically acceptable vehicles, excipients, diluents, and adjuvants.
    Type: Application
    Filed: August 9, 2013
    Publication date: February 12, 2015
    Applicant: National Taiwan University
    Inventors: Chao-Ying CHEN, Chia-Hua LIN, Min-Wei CHANG
  • Publication number: 20150045286
    Abstract: Arylomycin analogs are provided, wherein the analogs can have broad spectrum bioactivity. Resistance to the antibiotic bioactivity of natural product arylomycin in a range of pathogenic bacterial species has been found to depend upon single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases), wherein the presence of a proline residue confers arylomycin resistance. Arylomycin analogs are provided herein that can overcome that resistance and provide for a broader spectrum of antibiotic bioactivity than can natural product arylomycins such as arylomycin A2. Methods for determining if a bacterial strain is susceptible to narrow spectrum arylomycin antibiotics, or if a broad spectrum analog is required for treatment, is provided. Pharmaceutical compositions and methods of treatment of bacterial infections, and methods of synthesis of arylomycin analogs, are provided.
    Type: Application
    Filed: March 8, 2013
    Publication date: February 12, 2015
    Inventors: Floyd E. Romesberg, Peter A. Smith, Tucker C. Roberts
  • Publication number: 20150038407
    Abstract: The present invention relates to novel agents, pharmaceutical compositions containing them, and theft use in therapy, particularly anti-microbial and anti-cancer therapy. In particular, the present invention relates to novel peptide-based compounds based on SEQ ID NO: 40 which have surprisingly been shown to have inhibitory effects on the growth and/or viability of cells, particularly bacterial and cancer cells. Also provided are therapeutic and non-therapeutic methods which include the use of peptides of the invention.
    Type: Application
    Filed: June 16, 2014
    Publication date: February 5, 2015
    Inventor: Lars Prestegarden
  • Publication number: 20150030566
    Abstract: Compositions containing one or more tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts and plant material are described herein. The active agents used to control these pathogens are tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives, analogues or modifications thereof.
    Type: Application
    Filed: August 22, 2013
    Publication date: January 29, 2015
    Inventors: Marina Rautenbach, Abré De Beer, Anscha Mari Troskie, Johan Arnold Vosloo
  • Publication number: 20150031602
    Abstract: Provided are compounds, the use of the said compounds in treatment, for example treatment of microbial infections, particularly by Gram negative bacteria. The compounds are polymyxin-based and are represented by the formula (I): and pharmaceutically acceptable salts thereof, where X is —NHC(O)—, —C(O)—, —OC(O)—, —CH2— or —SO2—; R5 represents C0-12 alkyl(C4-6 heterocyclyl), or C2-12 alkyl or C0-12 alkyl(C3-8 cycloalkyl). and the alkyl or cycloalkyl bears one, two or three hydroxyl groups, or a —NR6R7 group, or one —NR6R7 group and one or two hydroxyl groups; and R1 to R4 and R6 to R8 are as defined in the description.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 29, 2015
    Applicants: CANTAB ANTI-INFECTIVES LIMITED, NOVACTA BIOSYSTEMS LIMITED
    Inventors: Mona Saadi, Esther Duperchy, Pamela Brown, Michael John Dawson, Sjoerd Nicolaas Wadman
  • Patent number: 8940687
    Abstract: Antimicrobial compositions based upon stabilized angiogenin compositions also contain osteopontin and antimicrobial proteins such as lactoperoxidase (LPO), myeloperoxidase (MPO), salivary peroxidase (SPO) and lysozyme.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: January 27, 2015
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
  • Patent number: 8937040
    Abstract: Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the antibacterial compound, as well as methods for preparing the antibacterial compound.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 20, 2015
    Assignee: BioSource Pharm, Inc.
    Inventor: Richard A. Leese
  • Publication number: 20150018269
    Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.
    Type: Application
    Filed: August 24, 2012
    Publication date: January 15, 2015
    Applicants: UNIVERSITÄT ZU KÖLN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Ronald Kühne, Hartmut Oschkinat, Robert Opitz, Matthias Müller, Hans-Günther Schmalz, Cedric Reuter, Peter Huy
  • Publication number: 20150018268
    Abstract: The present invention relates to the use of a multivalent synthetic compound, which is significantly more resistant to at least one protease than a standard peptide bond, for preparing a medication, and methods of use for the treatment of diseases, e.g., due to bacterial and/or microbial growth.
    Type: Application
    Filed: October 4, 2011
    Publication date: January 15, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ELRO PHARMA, UNIVERSITE PARIS 12 - VAL DE MARNE
    Inventors: Robert H. Zimmer, José Courty
  • Patent number: 8933017
    Abstract: A method for treatment of infection with Listeria spp., Plasmodium spp., or Shigella spp. includes administering a peptide or a pharmaceutically acceptable salt of the peptide to an individual in need of treatment for the infection.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: January 13, 2015
    Assignee: Karlsruher Institut fur Technologie
    Inventors: Christian Jung, Véronique Orian-Rousseau, Alexandra Matzke, Helmut Ponta
  • Publication number: 20150011464
    Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 8, 2015
    Inventors: Ragnhild Weel-Sneve, James Alexander Booth, Magnar Bjørås, Knut Ivan Kristiansen
  • Publication number: 20140371134
    Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 18, 2014
    Inventor: Jay Richard Ray, II
  • Patent number: 8906365
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: December 9, 2014
    Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: 8906866
    Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 9, 2014
    Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
    Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
  • Patent number: 8901071
    Abstract: The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: December 2, 2014
    Assignee: Novabiotics Limited
    Inventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
  • Patent number: 8889121
    Abstract: The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: November 18, 2014
    Assignee: The Arizona Board of Regents for an on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Qingke Kong
  • Patent number: 8889826
    Abstract: Disclosed herein are novel peptides and protected peptides. These compounds can be derived from naturally occurring peptides, such as those selected from colistin, circulin A, polymyxin A, polymyxin B, polymyxin D, octapeptin B, octapeptin C, and [Ile7]polymyxin B1. Also disclosed are pharmaceutical compositions containing the new peptides, as well as methods for preparing the novel peptides and protected peptides.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: November 18, 2014
    Assignee: BioSource Pharm, Inc.
    Inventors: Richard A. Leese, Noreen Francis, William V. Curran, Donald B. Borders, Howard Jarolmen
  • Publication number: 20140329739
    Abstract: Disclosed are an antibiotic peptide and the like, having an amino acid sequence of Ac-Phe-Lys-Lys-Leu-Lys-Lys-Leu-Phe-Ser-Lys-Leu-Trp-Asn-Trp-Lys-NH2 (SEQ ID No:1). Also disclosed are a method of preparing the antibiotic peptide and the like, and the application thereof. The antibiotic peptide and the like synthesized by the solid phase synthetic technology according to the present invention can be used as a formulation against microbial infection and as alternate or adjuvant medicaments of antibiotics in the prior art.
    Type: Application
    Filed: January 17, 2012
    Publication date: November 6, 2014
    Applicant: JIANGSU PROTELIGHT PHARMACEUTICAL & BIOTECHNOLOGY CO., LTD.
    Inventors: Yuxin Chen, Mingxia Chen, Yibing Huang, Yang Li, Yong Wang, Lili Qu, Wenren Wang
  • Patent number: 8877161
    Abstract: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 4, 2014
    Assignee: Georgia Regents Research Institute, Inc.
    Inventors: Robert Yu, Han-Chung Wu
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn